PTPI - Petros Pharmaceuticals, Inc. Stock Price, Fair Value and News

$0.280.00 (0.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PTPI Price Action

Last 7 days

-17.6%


Last 30 days

-28.2%


Last 90 days

-17.6%


Trailing 12 Months

-76.9%

PTPI RSI Chart

MayJunJulAugSepOctNovDec20250102030405060708090

PTPI Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.59

Price/Sales (Trailing)

0.48

EV/EBITDA

0.93

Price/Free Cashflow

-0.48

PTPI Price/Sales (Trailing)

20222023202402468

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PTPI Fundamentals

PTPI Revenue

Revenue (TTM)

5.8M

Rev. Growth (Yr)

-5.87%

Rev. Growth (Qtr)

10.9%

202020212022202320246M8M10M12M14M16M

PTPI Earnings

Earnings (TTM)

-4.7M

Earnings Growth (Yr)

51.19%

Earnings Growth (Qtr)

-235.43%

20202021202220232024-30M-25M-20M-15M-10M-5M

PTPI Profitability

EBT Margin

-81.19%

Return on Equity

-151.72%

Return on Assets

-22.84%

Free Cashflow Yield

-208.01%

PTPI Investor Care

Shares Dilution (1Y)

355.00%

Diluted EPS (TTM)

-4.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20202021202220236M8M10M12M14M16M
Net sales
YearQ1Q2Q3Q4
20240000
20236.3M6.7M7.0M5.8M
20227.4M6.9M6.4M6.0M
202111.8M12.9M11.6M7.8M
202014.1M12.6M11.1M9.6M
201900015.6M
Get all data in R, Python etc through our Historical Stock Data APIs
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Petros Pharmaceuticals, Inc.? What does PTPI stand for in stocks?

PTPI is the stock ticker symbol of Petros Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Petros Pharmaceuticals, Inc. (PTPI)?

As of Thu Jan 30 2025, market cap of Petros Pharmaceuticals, Inc. is 2.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTPI stock?

You can check PTPI's fair value in chart for subscribers.

Is Petros Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PTPI is over valued or under valued. Whether Petros Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Petros Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTPI.

What is Petros Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jan 30 2025, PTPI's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 0.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTPI PE ratio will change depending on the future growth rate expectations of investors.